eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).
eFFECTOR Therapeutics became a publicly listed company on August 26, 2021 after completing a business combination with Locust Walk Acquisition Corp., a publicly traded special purpose acquisition company. Forge no longer actively tracks this company.
What is eFFECTOR Therapeutics's ticker symbol?
What is eFFECTOR Therapeutics's stock price?
0.363343 as of 3/27/23
eFFECTOR Therapeutics Funding Rounds and IPO Valuation
Price per Share
Based on primary financings
Learn more about eFFECTOR Therapeutics
What is eFFECTOR Therapeutics funding to date?
eFFECTOR Therapeutics has raised $152.08MM with the following series: $67.04MM for Series A, $141.22MM for Series B, $197.73MM for Series C, $67.04MM for Series A, $141.22MM for Series B, $197.73MM for Series C.